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Abstract
Cystic ﬁbrosis (CF) is a life-shortening genetic disease characterized by variability in age of death that is largely due to variability in rate
of progression of lung disease, the primary cause of mortality. Recognizing which individuals have more aggressive disease phenotypes and
predicting their risk of immediate lung disease progression is a critical step in managing CF lung disease and extending the life expectancy
of CF patients. Studies using observational CF patient registries have yielded useful methods for predicting future rate of disease progression
and can be used to determine the impact that chronic pulmonary therapies have on slowing rate of lung function decline.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
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1. Introduction
Cystic ﬁbrosis (CF) is a common life-shortening, childhood
onset inherited disorder that affects the lungs, pancreas
and other organ systems [1]. Each year, approximately
1,000 persons in the United States receive a diagnosis
of CF [2]. Although both the median age of death and
expected median survival of persons with CF in the US have
steadily increased, > 80% of premature deaths continue to
result directly or indirectly from loss of lung function [3].
For this reason, spirometric measurements of lung function
(particularly forced expiratory volume in 1 second; FEV1)
are important surrogate measures of disease progression and
survival in CF.
Unfortunately, conventions around the use of FEV1 (and
more importantly, that fraction of FEV1 retained relative to
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a “predicted” FEV1 based on age, sex, and height: FEV1
% predicted) to deﬁne CF lung disease can be confusing,
and at times contradictory. For instance, it is common for
age-independent grouping of patients by FEV1 % predicted
to be referred to as stratiﬁcation by “disease severity”,
with labels of “severe, moderate, mild, and asymptomatic”
assigned to different subgroups. In this context, “severity” is
a cross-sectional term referring to the degree of pathologic
deterioration of the lung, and might better be substituted
with terms such as “condition” or “stage”. Confusion arises
because CF is a progressive, life shortening disease, and
the severity should correlate with length of survival, with
more rapid progression and earlier death identiﬁed as a more
“severe” disease course. For example, a 10 year old and a 30
year old with CF and 40% of their predicted FEV1 values are
at the same stage of lung destruction, but it is clear that the
severity of their respective disease courses has been different.
The 30 year old has clearly experienced slower progression
and has had a milder disease course than the 10 year old, even
though they are currently at similar stages of lung disease.
At some point earlier in life, the 10 year old was at an early
stage of lung disease, but given the rapidity of lung disease
progression, was “mild” ever an appropriate label for this
child’s CF lung disease?
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Confusion of disease stage with disease severity may
be more than a simple semantic issue; epidemiologic data
suggest that clinical intervention is much more intense in CF
patients with advanced lung disease than at earlier stages [4].
Yet there are young CF patients with aggressive disease who
are at high risk for rapid progression and who might beneﬁt
from more rigorous intervention at early stages. Does deﬁning
their lung disease severity as “mild” enable this process, or
does it reinforce a “wait and see” attitude that these patients
can hardly afford?
The aim of this paper is to clarify distinctions between CF
lung disease stage and severity of afﬂiction, and to suggest
that recent insights into estimation of risk of future lung
disease progression using patient risk factors can improve
the rationale (and presumably the beneﬁts) of therapeutic
intervention in CF.
2. Assessing disease severity using decline in FEV1
The course of lung disease in persons with CF can be
described by plotting their FEV1 % predicted throughout their
lifetime (Fig. 1). Although traditional spirometry cannot be
reliably performed under the age of 6 years, we believe that
lung function is essentially normal (i.e. at 100% of predicted
value) for newborns with CF. As lung disease progresses
with age, FEV1 % predicted is lost, and the rate of disease
progression at any given time is represented by the slope
of this curve (as FEV1 % predicted/year; Fig. 1A). Both
prospective and retrospective analyses have suggested that the
age at which this curve intersects with 20% predicted can
predict age of death [5,6]. Fig. 1A is an idealized depiction
of such a plot; Fig. 1B shows this idealized plot overlaid with
actual cross-sectional data from all patients at a single CF
center, demonstrating that there is a high degree of variability
in progression of CF lung disease (i.e. that there is not a single
disease course as in Fig. 1A, but rather that there are multiple
possible courses, as in Fig. 1B).
Understanding this variable rate of progression is integral
to appreciating the distinction between the aggressiveness of
Fig. 1. Plotting FEV1 % predicted versus age. Panel A: The disease course of a hypothetical CF patient. FEV1 % predicted is not reliably collected before
age 6 (gray box). At any given time, the curve slope is a measure of rate of lung function decline (as FEV1 % predicted/yr). Estimation of when this curve
will intersect with 20% FEV1 predicted is a robust predictor of age of death (in this case, approximately 26 years). Panel B: Overlay of data for all patients
from a single CF care center at a given time. Additional curves have been added to reﬂect the diversity of disease courses within this population. Curves that
intersect with 20% predicted earlier in time represent populations with more aggressive disease courses and earlier mortality. Curves that intersect later in time
represent less aggressive disease courses.
Fig. 2. Comparison of disease aggressiveness of different CF populations.
A, B, and C represent three distinct CF populations. Populations A and
B are the same age, but differ by 10% FEV1 predicted. Populations B
and C have the same FEV1 % predicted, but differ in age by 10 years.
Hypothetical disease course curves allow comparison of the relative disease
aggressiveness associated with these populations.
an individual’s CF disease phenotype and the stage of their
lung disease, and why an individual’s FEV1 % predicted
alone is inadequate to characterize the aggressiveness of their
disease. The idealized progression curves in Fig. 1B illustrate
variability of disease phenotype. The earlier in time that a
given curve intersects 20% FEV1 predicted, the earlier the
predicted age of death for patients following that curve, and
thus the more aggressive their phenotype. This method of
representation helps explain two epidemiologic observations.
First, for two groups of CF patients of the same age but
with a 10 point difference in FEV1 % predicted (e.g. groups
A and B of Fig. 2), the group with the lower FEV1 (group
B) has a two-fold lower 2-year survival compared to the
other group. Second, for two groups of CF patients with
the same FEV1 % predicted but 10 years difference in age
(e.g. groups B and C of Fig. 2), the younger group (group
B) has a two-fold lower 2-year survival relative to the older
group [7]. While it may seem obvious that group B has
demonstrated a more aggressive disease phenotype than group
A, it may not be obvious that group A has expressed a more
aggressive phenotype than group C, even though group C
is at a more advanced stage of disease. This is a situation
where the historical precedent of referring to disease stage as
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Fig. 3. Topography of disease stage and disease aggressiveness. Panel A: Division of the CF population into three lung disease stages (early, intermediate, and
advanced) based upon FEV1 % predicted. Populations A and B from Fig. 2 are at different stages, while populations B and C are at the same stage of disease.
Panel B: Division of population based upon aggressiveness of lung disease. This topographical depiction is adapted from an analysis by Schluchter et al. [8]
modeling the least and most aggressive CF disease course quartiles among F508 homozygotes. Using this algorithm, population B from Fig. 2 has the most
aggressive disease, and the aggressiveness of population A is likely greater than that of population C, even though population A is at an earlier disease stage.
“disease severity” can cause confusion, since groups B and
C are at the same disease stage (Fig. 3A), but likely differ
with respect to disease aggressiveness. A “topographical”
depiction of CF lung disease aggressiveness as a function of
FEV1 % predicted and age as generated by Schluchter et al.
[8] illustrates this point (Fig. 3B).
3. Risk factors that predict rate of FEV1 decline
Although the age and the FEV1 % predicted of an
individual can help identify the relative aggressiveness of
their CF phenotype, they do not necessarily provide a good
prediction of the risk that an individual has for future rapid
disease progression. In other words, they can tell you where
a patient has come from, but not necessarily where they are
going. Given that the goal of pulmonary interventions are
ultimately to retard the disease process and thereby reduce the
rate of lung function decline, the ability to predict future rate
of decline is essential for making rational decisions regarding
intervention.
A number of studies conducted at single treatment cen-
ters and/or with small numbers of patients have identiﬁed
factors associated with an increased risk of future lung
disease progression. These include, but are not limited to,
young age, high lung function, female sex, certain CFTR
genotypes and modiﬁer genes, pancreatic insufﬁciency, poor
nutritional status, lower socioeconomic status, respiratory
viral infections, infection with Pseudomonas aeruginosa or
Burkholderia cepacia, and diabetes mellitus. More recently,
the Epidemiologic Study of Cystic Fibrosis (ESCF) [9], a
multicenter, prospective encounter-based observational study
of over 30,000 CF patients conducted in the US and Canada
from 1994 to 2005, was used to assess these and other poten-
tial risk factors for FEV1 decline in children and adolescents
with CF. 4,923 patients aged 6–17 years were studied by
repeated-measures mixed model regression to estimate mean
rates of change of FEV1 % predicted and the inﬂuence of po-
tential risk factors identiﬁed in the previous year on observed
rates. Patients were stratiﬁed into age groups of 6 to 8 years,
Table 1
Risk factors for decline in FEV1 for children and adolescents in any of the
age groups 6 to 8 years, 9 to 12 years, and 13 to 17 years (adapted from
Konstan et al. [10])
– Baseline FEV1
– Gender
– P. aeruginosa in last sputum culture during the past year
– Weight-for-age percentile at last clinic visit during the past year




– Annual incidence of exacerbations treated with i.v. antibiotic
– Elevated liver function tests *
– Pancreatic enzyme use *
*Condition present during >50% of visits during the past year.
9 to 12 years, and 13 to 17 years, and studied over a mean
observation period of 5.5 years [10].
Of 28 potential risk factors investigated, 11 had a signiﬁ-
cant univariate association with rate of FEV1 decline in any
age group, and were retained in the ﬁnal multiple regression
analysis (Table 1). Overall rates of decline were −1.12,
−2.39 and −2.34% predicted per year in 6–8-year-olds, 9–
12-year-olds and 13–17-year-olds, respectively. Statistically
signiﬁcant risk factors for all age groups were high base-
line FEV1, sex, and the presence of crackles. In contrast,
other previously recognized risk factors were only found to
be statistically signiﬁcant in two of the three age groups
studied: Pseudomonas infection was not a signiﬁcant risk
factor in 13–17-year-olds, intravenous antibiotic treatment for
pulmonary exacerbation was not a signiﬁcant risk factor in
9–12-year-olds, and daily sputum production and low weight
for age were not signiﬁcant risk factors in 6–8-year-olds.
Using this more comprehensive analysis, it is now possible
to predict the rate of an individual child or adolescent’s lung
function decline over the next 4 years based on his or her
clinical history by adding the independent effect of each risk
factor exhibited by the patient to the overall rate of decline
for his or her age group [10]. For example, a 10-year-old
S18 M.W. Konstan et al. / Journal of Cystic Fibrosis Volume 8 Suppl 1 (2009) S15–S19
boy with pancreatic insufﬁciency, FEV1 of 103% predicted,
weight-for-age at the 20% percentile and a positive culture
for Pseudomonas, but no other identiﬁed risk factors, can be
predicted to lose 3.22% predicted FEV1 per year, i.e. 13%
predicted over the next 4 years.
Risk factors for poor future lung function in children
under 6 years old were assessed in an earlier ESCF analysis
in which FEV1 at age 6 years was correlated with clinical
characteristics exhibited at 3 years of age [11]. Low weight-
for-age and height-for-age percentiles as well as the presence
of crackles, Pseudomonas infection, daily sputum, cough and
clubbing at age 3 were all associated with lower FEV1 at 6
years of age.
4. Therapies associated with slowing decline in FEV1
As mentioned earlier, the value of determining an individ-
ual’s CF lung disease aggressiveness (independent of disease
stage) and predicting their future risk of lung function decline
is best realized when interventions known to retard rate of
decline can be administered. Unfortunately, there are little
data to demonstrate that most commonly used chronic CF
pulmonary therapies impact rate of lung function decline.
Because of variability in disease course and rate of decline
over short time periods, randomized clinical trials have almost
exclusively focused on ‘sustained improvement’ in lung func-
tion as the pulmonary outcome measure, which may or may
not translate into slower decline. Prospective demonstration of
a therapeutic impact on rate of lung function decline requires
observation over periods of several years [12] and to date
only one chronic CF therapy, high dose ibuprofen, has been
prospectively shown to impact lung function decline [13,14].
The availability of large CF patient registries has made
it possible to retrospectively test whether chronic pulmonary
therapies have impacted CF lung function decline, although
these analyses are complicated and not without signiﬁcant
limitations. Nevertheless, a retrospective analysis of high dose
ibuprofen use, employing the CF Foundation Patient Registry,
has demonstrated that such relationships can be detected [15].
Of the 6–17-year-old patients with FEV1 >60% predicted who
were in the Patient Registry between 1996 and 2000, 1,365
patients were treated with ibuprofen while 8,960 patients were
not. The rate of decline in FEV1 was compared in treated
versus untreated patients using an analysis that adjusted for
several risk factors [15]. Over an average observation period
of 2–7 years, the mean annual rate of decline in FEV1 %
predicted was 27% slower in patients treated with ibuprofen
(−1.48% predicted/yr) than in untreated patients (−2.08%
predicted/yr).
The ESCF observational study is also being used to assess
the effect of various therapies on lung function decline. The
ﬁrst reported analysis of this type evaluated the use of inhaled
corticosteroids [16]. Chronic inhaled corticosteroids were
used by 2,978 patients 6–17 years old. FEV1 decline changed
from −1.52 to −0.44% predicted per year after initiation
of this therapy. In a second analysis of 2,230 patients 8–38
years old followed for at least 4 years, initiating dornase alfa
was associated with a statistically signiﬁcant reduction in the
rate of decline in FEV1 relative to a comparator group [17].
It is likely that other therapies will be similarly studied in
the future. Such studies will provide important reassurance
that chronic therapies, which can represent both additional
treatment burden and cost to patients and caregivers, are
capable of modifying CF lung disease progression.
5. Conclusions
FEV1 % predicted is a surrogate for survival in CF
patients that is used to identify the stage of CF lung disease
progression. Traditionally CF lung disease stage has been
termed “disease severity” with categories of “asymptomatic
mild, moderate, or severe”, but this terminology does not
account for the effect of age in deﬁning disease severity. The
problem is most obvious when a child is at an early stage of
a very aggressive lung disease course. Although at an early
stage of lung disease, this child is unlikely to reach adulthood
and there will never be anything “mild” about the severity
of his or her afﬂiction. If we contrast this hypothetical CF
child with an adult male with near-normal lung function who
has been recently diagnosed with CF due to infertility, their
relative lung functions may be their only shared characteristic.
To the extent that qualiﬁers such as “mild” or “severe” disease
impact a clinician’s willingness to intervene therapeutically,
they are best reserved for describing the aggressiveness of
disease phenotype.
The rate at which FEV1 % predicted declines at any time in
a patient’s life is an important indicator of the aggressiveness
of their CF lung disease, independent of their lung disease
stage. The high variability of an individual’s FEV1 %
predicted over short periods prohibits accurate estimation of
an individual’s current rate of lung function decline, with
several years of data collection required to obtain reasonable
estimates [12]. Unfortunately, an individual’s past rate of
decline is not predictive of immediate future decline. For
instance, young patients that have lost little to no FEV1 are
at the greatest risk of immediate rapid decline [10]. Further,
there is no opportunity to mitigate past FEV1 decline through
disease management. Longitudinal analyses have identiﬁed
risk factors for future FEV1 decline in various age groups
that allow us to predict future disease aggressiveness. The
ability to identify patients that may “appear” to be at low risk
(primarily because they are at an early stage of lung disease)
but are determined to actually be at high risk for decline
allows clinicians to rationally consider the risks and beneﬁts of
interventions that may slow the rate of lung function decline.
Recognition that producing a “sustained improvement” in
lung function may not equate to a reduction in the rate of
lung function decline has stimulated retrospective analyses
of observational databases to determine which chronic CF
pulmonary therapies may in fact be disease modifying. As
these analyses are published, the ability to selectively and
aggressively target higher risk individuals, regardless of their
disease stage, has the potential to dramatically improve overall
survival in CF.
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